Summary
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
History
Clarus Therapeutics was established in 2005 as a small specialty pharmaceutical company. Initially, Clarus focused on the development of therapies to treat BPH, erectile dysfunction, prostate cancer and other men's health issues. In 2014, the company expanded to include a commercial arm, providing products directly to clinicians and patients. Clarus now boasts more than 20 products across several therapeutic areas with plans for further expansion.
Mission
Our mission is to provide patients and clinicians with innovative, proven treatments for the most pressing men's health conditions. We strive to develop products that provide safe and effective results that can be tailored to fit each individual patient’s needs.
Vision
Our vision is to become the go-to source for men’s health solutions. We strive to provide comprehensive, top-quality treatments to all our customers, ensuring that everyone has access to treatments that improve and maintain their overall health.
Key Team
Mr. Mike Cleveland (VP of Sales)
Mr. James Holloway (Sr. VP of Manufacturing & Supply)
Dr. Jay Newmark M.B.A., M.D. (Chief Medical Officer)
Mr. Lawrence Perkins (Chief Restructuring Officer)
Recognition and Awards
Clarus Therapeutics has been recognized for its achievements by several organizations including the American Pharmaceutical Association, American Urological Association, Medical Marketing Association and the Advertising Research Foundation. Clarus has also won the Innovation Award and Best Practice Award from the National Association of Specialty Pharmacies.
References
